New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - etoposide 50mg - capsule - 50 mg - active: etoposide 50mg excipient: citric acid monohydrate gelatin glycerol   iron oxide red macrogol 400 propyl hydroxybenzoate sodium ethyl hydroxybenzoate titanium dioxide water  

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - erythromycin lactobionate, quantity: 1.4882 g/g (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - oral erythromycin is not considered to be the antibiotic of choice in severely ill patients.,erythromycin-link (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time.,? upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).,? lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae).,? respiratory tract infections due to mycoplasma pneumoniae.,? skin and s

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - adrenaline acid tartrate -

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - verteporfin 15mg - powder for infusion - 15 mg - active: verteporfin 15mg excipient: ascorbyl palmitate butylated hydroxytoluene dimyristoylphosphatidylcholine lactose monohydrate phosphatidylglycerols - visudyne is indicated for the treatment of patients with predominately classic or occult subfoveal choroidal neovascularisation due to age-related macular degeneration (amd), or with subfoveal choroidal neovascularisation caused by other macular diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - argipressin, quantity: 1 mg - injection, solution - excipient ingredients: water for injections; acetic acid - pitressin is used in the prevention and treatment of postoperative abdominal distension; in abdominal radiography to dispel interfering gas shadows and in diabetes insipidus.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - chloramphenicol sodium succinate (equivalent: chloramphenicol, qty 1 g) - injection, powder for - excipient ingredients: - chloromycetin succinate is specifically indicated for bacterial meningitis, typhoid fever, rickettsial infections, intra ocular infections, other serious infections where bacteriological evidence or clinical judgement indicates that chloramphenicol is appropriate antibiotic.

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - phenelzine sulfate 25.83mg equivalent to phenelzine 15 mg - film coated tablet - 15 mg - active: phenelzine sulfate 25.83mg equivalent to phenelzine 15 mg excipient: magnesium stearate maize starch mannitol opadry red 20a25096 povidone - for the treatment of major depression. phenelzine sulfate should rarely be the first antidepressant medicine used. rather it is more suitable for use with patients who have failed to respond to the medicines more commonly used for these conditions

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - foscarnet sodium hexahydrate 24 mg/ml - solution for infusion - 24 mg/ml - active: foscarnet sodium hexahydrate 24 mg/ml - treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids). treatment of acyclovir resistant herpes simplex virus (hsv) infections in immunocompromised patients. the safety and efficacy of foscavir for the treatment of other hsv infections (e.g. retinitis, encephalitis); congenital or neonatal disease; or hsv in immunocompetent individuals has not been established.

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - hydrocortisone butyrate 0.1%;   - scalp lotion - 0.1 % - active: hydrocortisone butyrate 0.1%   excipient: citric acid glycerol isopropyl alcohol povidone purified water sodium citrate

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - hydrocortisone butyrate 0.1%;   - topical ointment - 0.1 % - active: hydrocortisone butyrate 0.1%   excipient: liq. paraf. gel with 5% poyethylene oleogel to 100%.